In chronic myelogenous leukemia (CML), a reciprocal balanced chromosomal translocation in haematopoietic stem cells produces the BCR-ABL hybrid gene, which encodes a constitutively activated kinase. STI571, marketed as imatinib, is a potent ATP-competitive inhibitor of c-Abl (IC50 188 nM). Despite the efficacy of the drug in stable-phase CML, in advanced leukemias, where there is a high frequency of DNA mutation, many patients relapse with point mutations in the kinase domain. We have determined the crystal structure of STI571 in complex with human Abl kinase (spacegroup C2221) and determined the inhibitry activity of STI571 towards many of the Abl kinase mutants. The structure shows that STI571 stabilises an inactive conformation of the protein, thus comfirming Schindlers findings (Science 2000 (Science , 289:1938 (Science -1942 for murine Abl-kinase in complex with a structurally-related inhibitor (spacegroup F222). These studies allow us to rationalise the decreased sensitivity of mutant Bcr-Abl to STI571. Point mutations such as T315I in the ATP-binding site result in loss of a hydrogen bond and steric hindrance to the binding of STI571 (IC50T315I (STI571) > 10 µ M). Mutations in the glycine-rich loop such as E255V (IC50 (STI571) 3.5 µ M), E255K and Y253H (IC50 (STI571) >10 µ M), destabilise the unusual conformation that this loop adopts in the inactive state, as does H396P in the activation loop. The variety and spread of these and other mutants makes it a challenge to design drugs to overcome resistance. Mitochondrial Cyclophilin D (CypD) belongs to a family of cyclosporin-A binding proteins, which catalyse rotation about prolyl peptide bonds. Structures of the three other types of mammalian cyclophilins (A, B and C) are known, but crystallization of CypD has not been reported yet. A truncated version of CypD with the same length as CypA was expressed in Escherichia coli and purified to homogeneity. The protein shows a monodisperse size distribution in dynamic light scattering, but crystallization trials gave no crystals. Therefore, site-directed mutagenesis was used to obtain a variant of CypD suitable for crystallization and structure determination. A series of mutants was selected such that crystal contacts seen in the X-ray structures of CypA would be restored or the unusually high solubility and isoelectric point (pI) of 10.3 reduced. The crystals of the mutant K133I were most promising and yielded readily crystals diffracting to 1.5 Å resolution using in house data collection facilities -an excellent basis for structure based drug design. This encouraging result shows that surface mutations have a dramatic effect on the protein and are a powerful tool for the improvement of protein crystallisation properties. This crystallographic system was successfully used to confirm hits from screening by biophysical methods (NMR, SPR and fluorescence studies) and to guide improvements of small molecule binding to cyclophilin D by structure based drug design. Aldose Reductase, an enzyme involved in diabetes complications, is the target of an extended effort in inhibitor development. Previous work has showed the existence of an anchoring point in the active site to which the carboxylate head of inhibitors can be bound. The carboxylate head mimics the transient enolate state of the substrate, and binds the two catalytic residues, Tyr 48 and His 110. Different orientations of the carboxylate have been observed, depending on the pH of the crystallisation conditions and on the inhibitor. In each previous case, the carboxylate has been well ordered, especially in the complex that was crystallized at pH 5 and that led to a subatomic resolution (0.66 Å) structure. We have obtained crystals of the same complex at pH 8 as well, and solved the structure at 1.5 Å resolution. The conformations of most of the inhibitor are very close to each other at pH 5 and pH 8 but clearly shows two alternative conformations of the carboxylate head. These conformations correspond to optimising the hydrogen bond geometry with the His 110 and the Tyr 48 respectively, and could correspond to alternative catalytic mechanisms in which the proton donor is either His110 or Tyr48.
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